Abstract
Background. Interleukin‐3 (IL‐3) is an experimental agent used to ameliorate neutropenia in patients receiving chemotherapy. Arterial thrombotic episodes after use of IL‐3 have not been reported previously. Methods. The case of a patient with Stage III adenocarcinoma of the breast who developed hypotension and acute cerebellar artery and superior mesenteric artery thrombosis after receiving chemotherapy and treatment with IL‐3 is reported. Results. To the authors' knowledge, this is the first patient with arterial thrombosis reported after treatment with IL‐3. Conclusions. Interleukin‐3 may be associated with increased propensity for thrombosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2808-2810 |
| Number of pages | 3 |
| Journal | Cancer |
| Volume | 74 |
| Issue number | 10 |
| DOIs | |
| State | Published - Nov 15 1994 |
Fingerprint
Keywords
- arterial thrombosis
- breast cancer
- hypercoagulable state
- interleukin 3
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5‐fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin‐3. / Theodossiou, C.; Kroog, G.; Ettinghausen, S.; Tolcher, A.; Cowan, K.; O'Shaughnessy, J.
In: Cancer, Vol. 74, No. 10, 15.11.1994, p. 2808-2810.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5‐fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin‐3
AU - Theodossiou, C.
AU - Kroog, G.
AU - Ettinghausen, S.
AU - Tolcher, A.
AU - Cowan, K.
AU - O'Shaughnessy, J.
PY - 1994/11/15
Y1 - 1994/11/15
N2 - Background. Interleukin‐3 (IL‐3) is an experimental agent used to ameliorate neutropenia in patients receiving chemotherapy. Arterial thrombotic episodes after use of IL‐3 have not been reported previously. Methods. The case of a patient with Stage III adenocarcinoma of the breast who developed hypotension and acute cerebellar artery and superior mesenteric artery thrombosis after receiving chemotherapy and treatment with IL‐3 is reported. Results. To the authors' knowledge, this is the first patient with arterial thrombosis reported after treatment with IL‐3. Conclusions. Interleukin‐3 may be associated with increased propensity for thrombosis.
AB - Background. Interleukin‐3 (IL‐3) is an experimental agent used to ameliorate neutropenia in patients receiving chemotherapy. Arterial thrombotic episodes after use of IL‐3 have not been reported previously. Methods. The case of a patient with Stage III adenocarcinoma of the breast who developed hypotension and acute cerebellar artery and superior mesenteric artery thrombosis after receiving chemotherapy and treatment with IL‐3 is reported. Results. To the authors' knowledge, this is the first patient with arterial thrombosis reported after treatment with IL‐3. Conclusions. Interleukin‐3 may be associated with increased propensity for thrombosis.
KW - arterial thrombosis
KW - breast cancer
KW - hypercoagulable state
KW - interleukin 3
UR - http://www.scopus.com/inward/record.url?scp=0027995408&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027995408&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19941115)74:10<2808::AID-CNCR2820741011>3.0.CO;2-V
DO - 10.1002/1097-0142(19941115)74:10<2808::AID-CNCR2820741011>3.0.CO;2-V
M3 - Article
C2 - 7954241
AN - SCOPUS:0027995408
VL - 74
SP - 2808
EP - 2810
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 10
ER -